











MIT GLOBAL **SCALE** NETWORK

January 2017 Poster Session

Sponsor: CVS Health and GlaxoSmithKline

Motivation / Background

Advisor: Bruce Arntzen



Potential counterfeit market:

- I. Pharma \$200bn
- II. Electronics \$169bn
- III. Food \$49bn



Drug Supply Chain Security Act (DSCSA)

- Unit level Serialization
- Item Level Track and Trace

Key Questions

- I. How DSCSA law impacts physical flow?
- II. What should IT architecture be?
- III. What is impact of "Push" vs "Pull" data model?

Relevant Studies

Food and Drugs Administration (FDA) documentation Parallel Processes in Other

- Industries: Aerospace, Food, Medical Devices
- Countries: China, India, Brazil, Turkey





The Problem

Pharma

Serial Info traceability with Physical Pallet Aggregation & Break Down







Expected Contribution

Serialization impact on data access, transmission, and security will be explored, along with physical inventory and investment requirements.

Distinct scenarios for study:

- A. Centralized information flow with data push model
- Decentralized information flow with data push model
- Centralized information flow with data pull model
- D. Decentralized information flow with data pull model









